Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib

M. Birch*, P. E. Morgan, S. Handley, A. Ho, R. Ireland, R.J. Flanagan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)

Abstract

A simple HPLC method has been developed to measure imatinib and N-desmethylimatinib (norimatinib) in plasma or serum at concentrations attained during therapy. Adaptation of this method to LC-MS/MS also allows dasatinib assay. A small sample volume (100 L HPLC-UV, 50 L LC-MS/MS) is required and analysis time is 1 mg/L (suggested target for response) in all but one sample from patients achieving complete molecular response. As to dasatinib, the median (range) plasma dasatinib concentration was 13 (2-143) mu g/L (N=33). More observations are needed to properly assess the potential role of therapeutic drug monitoring in guiding treatment with dasatinib.

Original languageEnglish
Pages (from-to)335-342
Number of pages8
JournalBiomedical Chromatography
Volume27
Issue number3
DOIs
Publication statusPublished - Mar 2013

Keywords

  • chronic myeloid leukaemia
  • dasatinib
  • imatinib
  • norimatinib
  • therapeutic drug monitoring
  • CHRONIC MYELOID-LEUKEMIA
  • TANDEM MASS-SPECTROMETRY
  • PLASMA-LEVELS
  • CHRONIC-PHASE
  • BCR-ABL
  • CLINICAL PHARMACOKINETICS
  • QUANTIFICATION
  • NILOTINIB
  • QUANTITATION
  • STI-571

Fingerprint

Dive into the research topics of 'Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib'. Together they form a unique fingerprint.

Cite this